TD Cowen Starts Biostage (BSTG) at Buy

TD Cowen analyst Charles Rhyee initiates coverage on Biostage (OTC: BSTG) with a Buy rating and a price target of $37.00.

The analyst comments "We initiate coverage of BrightSpring Health Services (BTSG) with a Buy rating and $37 PT. We believe BTSG, a leading oncology-focused specialty pharmacy and home health provider, stands to benefit from continued specialty growth and a generic wave driven by pharma's upcoming patent cliff. Our PT implies shares trade at 15x our FY26 adj EBITDA est."

For an analyst ratings summary and ratings history on Biostage click here. For more ratings news on Biostage click here.

Shares of Biostage closed at $4.03 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery